Cargando…

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis

BACKGROUND: Leukemia-associated macrophages (LAMs) represent an important cell population within the tumor microenvironment, but little is known about the phenotype, function, and plasticity of these cells. The present study provides an extensive characterization of macrophages in patients with acut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brauneck, Franziska, Fischer, Brit, Witt, Marius, Muschhammer, Jana, Oelrich, Jennyfer, da Costa Avelar, Pedro Henrique, Tsoka, Sophia, Bullinger, Lars, Seubert, Elisa, Smit, Daniel J, Bokemeyer, Carsten, Ackermann, Christin, Wellbrock, Jasmin, Haag, Friedrich, Fiedler, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791419/ https://www.ncbi.nlm.nih.gov/pubmed/36549780 http://dx.doi.org/10.1136/jitc-2022-004794

Ejemplares similares

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML
por: Brauneck, F., et al.
Publicado: (2021)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
por: Brauneck, Franziska, et al.
Publicado: (2023)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients
por: Jin, Zhenyi, et al.
Publicado: (2020)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer
por: Liu, Zhaopei, et al.
Publicado: (2020)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

TIGIT in Lung Cancer: Potential Theranostic Implications
por: Pescia, Carlo, et al.
Publicado: (2023)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
por: Judge, Sean J, et al.
Publicado: (2020)

An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
por: Zuo, Shuguang, et al.
Publicado: (2021)

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
por: Blessin, Niclas C., et al.
Publicado: (2019)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT limits immune pathology during viral infections
por: Schorer, Michelle, et al.
Publicado: (2020)

Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
por: Lucca, Liliana E., et al.
Publicado: (2020)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

Discovery of TIGIT inhibitors based on DEL and machine learning
por: Xiong, Feng, et al.
Publicado: (2022)

Expression and Clinical Significance of TIGIT in Primary Breast Cancer
por: Tang, Limin, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir
por: Holder, Kayla A., et al.
Publicado: (2020)

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
por: Fu, Wenyan, et al.
Publicado: (2021)

Implication of TIGIT(+) human memory B cells in immune regulation
por: Hasan, Md Mahmudul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9n9572iq75l2d67aukalsgsb5b